Publicaciones en las que colabora con Sandra Hervas Stubbs (47)

2023

  1. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

    EMBO Molecular Medicine, Vol. 15, Núm. 11

  2. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. Advances in immunotherapy for hepatocellular carcinoma

    Nature Reviews Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 525-543

  2. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

  2. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses

    Molecular Therapy, Vol. 27, Núm. 11, pp. 1892-1905

2015

  1. Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression

    Gene Therapy, Vol. 22, Núm. 11, pp. 856-865

  2. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12

    Cancer Research, Vol. 75, Núm. 3, pp. 497-507

2013

  1. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein

    Cancer Research, Vol. 73, Núm. 1, pp. 139-149

  2. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162

  3. Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

    Journal for ImmunoTherapy of Cancer, Vol. 1

  4. Interleukin-15 in gene therapy of cancer

    Current Gene Therapy, Vol. 13, Núm. 1, pp. 15-30

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic semliki forest virus encoding IL-12

    Molecular Therapy, Vol. 20, Núm. 9, pp. 1664-1675

  3. Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

    PLoS ONE, Vol. 7, Núm. 12

  4. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy

    Cancer Discovery, Vol. 2, Núm. 7, pp. 608-623

  5. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

    Journal of translational medicine, Vol. 10, pp. 122

2011

  1. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes

    Cancer Research, Vol. 71, Núm. 3, pp. 801-811

  2. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3